Cholecystokinin modulation of apomorphine- or amphetamine-induced stereotypy in rats: Opposite effects

Peptides

Volumn 22, Issue 8, 2001, Pages 1291-1298

  Tieppo, Carla A ^a   Felicio, Luciano F ^b   Nasello, Antonia G ^a  

^a Santa Casa de Misericordia de Sao Paulo   (Brazil)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

CCK4; CCK8; CCKA; CCKB; Dopamine; Stereotyped behavior

Indexed keywords

AMPHETAMINE; APOMORPHINE; CHOLECYSTOKININ; CHOLECYSTOKININ B RECEPTOR; CHOLECYSTOKININ OCTAPEPTIDE; CHOLECYSTOKININ RECEPTOR; DOPAMINE; TETRAGASTRIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG RESPONSE; MALE; NEUROMODULATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; RAT; STEREOTYPY; SULFATION;

AMPHETAMINES; ANIMALS; APOMORPHINE; CHOLECYSTOKININ; DOPAMINE; DOPAMINE AGONISTS; DRUG INTERACTIONS; MALE; RATS; RATS, WISTAR; RECEPTORS, CHOLECYSTOKININ; SINCALIDE; SYNAPSES; TETRAGASTRIN; TIME FACTORS;

EID: 0034907018     PISSN: 01969781     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0196-9781(01)00454-5     Document Type: Article

References (73)

1. A comparative study of the behavioral effects of d-amphetamine, and apomorphine in the rat
2. Behavioral effects of amphetamine and apomorphine after striatal lesions in the rat
3. SR146131: A new potent, orally active, and selective nonpeptide cholecystokinin subtype 1 receptor agonist. II. In vivo pharmacological characterization
4. Cholecystokinin B receptor antagonists enhance the locomotor response to the N-methyl-D-aspartate antagonists phencyclidine, and dizocilpine maleate
5. Neuropeptide modulation of apomorphine-induced stereotyped behavior
6. Modulation of motor behaviour by NMDA- and cholecystokinin-antagonism
7. Dopamine and N-methyl-D-aspartate receptor interactions in the neostriatum
8. Behavioral profile of parcial D2 dopamine receptor agonists
9. Cholecystokinin-octapeptide effects on conditioned-avoidance behavior, stereotypy, and catalepsy
10. Cholecystokinin potentiates dopamine-mediated behaviors: Evidence for modulation specific to a site of coexistence
11. Cholecystokinin-dopamine interactions
12. Subtype-selective cholecystokinin receptor antagonists block cholecystokinin modulation of dopamine-mediated behaviors in the rat mesolimbic pathway
13. Cholecystokinin modulates dopamine-mediated behaviors. Differential actions in medial posterior versus anterior nucleus accumbens
14. The expression of behavioral sensitization to amphetamine: Role of CCK(A) receptors
15. Neural basis of drug-induced yawning
16. Stereotyped behavior
17. Antipsychotic potential of CCK-based treatments: An assessment using the prepulse inhibition model of psychosis
18. Dopaminergic supersensitivity after long-term bromopride treatment
19. An observation method for quantifying the behavioural effects of dopamine agonists: Contrasting effects of d-amphetamine and apomorphine
20. A receptors
21. Cholecystokinin potentiates in vitro release of dopamine by the nucleus accumbens through type B CCK receptors
22. PD-135,158, a cholecystokinin (B) antagonist, enhances latent inhibition in the rat
23. Analysis of variation in L-365,260 competition curves in radioligand binding assays
24. Effects of CCK antagonists on CCK-induced suppression in locomotor activity in mice
25. A subpopulation of mesencephalic dopamine neurons projecting to limbic areas contains a cholecystokinin-like peptide: Evidence from immunohistochemistry combined with retrograde tracing
26. Immunohistochemical studies on cholecystokinin (CCK)-immunoreactive neurons in the rat using sequence specific antisera and with special reference to the caudate nucleus and primary sensory neurons
27. Amphetamine regulation of mesolimbic dopamine/cholecystokinin neurotransmission
28. Mechanisms of amphetamine action revealed in mice lacking the dopamine transporter
29. Interaction of CCK-B receptors with amphetamine in responding for conditioned rewards
30. Evidence for CCK(A) receptor involvement in the acquisition of conditioned activity produced by cocaine in rats
31. Disorders of thought: Schizophrenia
32. Systemic administration of CCK-8S, but not CCK-4, enhances dopamine turnover in the posterior nucleus accumbens: A microdialysis study in freely moving rats
33. Effects of cholecystokinin on apomorphine-induced changes of motility in rats
34. Ceruletide, a cholecystokinin-related peptide, attenuates haloperidol-induced increase in dopamine release from the rat striatum: An in vivo microdialysis study
35. Ceruletide, a CCK-like peptide, attenuates dopamine release from the rat striatum via a central site of action
36. Differential effects of ceruletide on amphetamine-induced behaviors and regional dopamine release in the rat
37. Decrease in exploratory behavior in naturally occurring cholecystokinin (CCK)-A receptor gene knockout rats
38. Alteractions in amphetamine-induced locomotor activity and stereotypy after electrical stimulation of the nucleus accumbens and neostriatum
39. CCK receptor polymorphisms: An illustration of emerging themes in pharmacogenomics
40. Effects of CCK-8 and of the CCKB-selective agonist BC264 on extracellular dopamine content in the anterior and posterior nucleus accumbens: A microdialysis study in freely moving rats
41. Different modifications of the dopamine metabolism in the core and shell parts of the nucleus accumbens following CCK-A receptor stimulation in the shell region
42. The CCK-B agonist, BC264, increases dopamine in the nucleus accumbens, and facilitates motivation, and attention after intraperitoneal (i.p.) injection in rats
43. Opposite effects of CCK(B) agonists in grooming behaviour in rats: Further evidence for two CCK(B) subsites
44. Different behavioural patterns induced by apomorphine: Evidence that the method of administration determines the behavioural response to the drug
45. Classification of neuroleptic drugs according to their ability to inhibit apomorphine-induced locomotion and gnawing: Evidence for two different mechanisms of action
46. Opposite effects mediated by CCKA and CCKB receptors in behavioural and hormonal studies in rats
47. Dopamine modulates cholecystokinin release in neostriatum
48. Differential role of cholecystokinin receptor subtypes in opioid modulation of ongoing maternal behavior
49. Cholecystokinin receptors
50. Immunohistochemical evidence for a crossed cholecystokinin corticostriatal pathway in the rat
51. Enkephalin prevents CCK-induced enhancement of amphetamine-induced locomotor stereotypy
52. Hypolocomotion induced by peripheral or central injection of CCK in the mouse is blocked by CCKA receptor antagonist devazepide but not by CCKB receptor antagonist L-365,260
53. Neurobehavioral effects of SR 27897, a selective cholecystokinin type A (CCK-A) receptor antagonist
54. The acquisition of responding with conditioned reinforcement: Effects of pipradrol, methylphenidate, d-amphetamine, and nomifensine
55. Lesion of the nigrostriatal pathway inducescholecystokinin messenger RNA expression in the rat striatum. An in situ hybridization histochemistry study
56. Effect of dopamine depletion upon the K(+)-evoked release of CCK from superfused striatal slices
57. L364,718 antagonizes the cholecystokinin-induced suppression of locomotor activity
58. Changes in pituitary-adrenal activity affect the apomorphine- and cholecystokinin-8-induced changes in striatal dopamine release using microdialysis
59. Intracerebroventricular administration of cholecystokinin reduces stereotypy in dopamine-supersensitive rats
60. Modulation of apomorphine-induced stereotyped behavior by cholecystokinin
61. Opposite modulation of apomorphine- or amphetamine-induced stereotypy by antagonists of CCK receptor
62. Reversal of increase in apomorphine-induced stereotypy and agression in REM sleep deprivated rats by dopamine agonists pretreatment
63. The effects of CCK-4 on dopamine D1 agonist-induced grooming are blocked by a CCK(A) receptor antagonist: Evidence for a novel CCK receptor subtype?
64. Evidence that type A CCK receptors facilitate dopamine efflux in rat brain
65. Nitric oxide mediate caerulein-induced suppression of locomotor activity
66. Cholecystokinin receptors
67. Opposite actions of CCK-8 on amphetamine-induced hyperlocomotion and stereotypy following intracerebroventricular and intra- accumbens injections in rats
68. CCK-8 injected into the nucleus accumbens attenuates the supersensitive locomotor response to apomorphine in 6-OHDA, and chronic-neuroleptic treated rats
69. Evidence for dopaminomimetic effect of intrastriatally injected cholecystokinin octapeptide in mice
70. On the origin of striatal cholecystokinin release: Studies with in vivo microdialysis
71. Modulation of neurotransmitter release by cholecystokinin in the neostriatum and substantia nigra of the rat: Regional and receptor specificity
72. Antistereotype effects od ceruletide and some neuroleptics differentiated by interactions with clonazepam, muscimol, scopolamine and clonidine